InvestorsHub Logo
Followers 27
Posts 1014
Boards Moderated 0
Alias Born 08/19/2016

Re: None

Tuesday, 01/03/2017 4:00:05 PM

Tuesday, January 03, 2017 4:00:05 PM

Post# of 403149
Cellceutix has successfully completed a Phase 2 clinical trial of Prurisol in patients with mild-to-moderate Chronic Plaque Psoriasis. Overall analyses showed the drug to appear safe, well-tolerated and efficacious in the highest dosing arm across 12 weeks of treatment. Patients with more moderate forms of psoriasis saw the greatest clinical improvements. Pharmacokinetic data further revealed an early and dose-dependent response that improved as treatment duration increased.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News